The latest news and research progress of molotinib/mometinib as the fourth generation targeted drugs

Momelotinib, as a targeted drug, has shown positive research progress and clinical application potential in the treatment of patients with myelofibrosis (MF) in recent years. Myelofibrosis is a rare hematopoietic system disease that is often accompanied by anemia, splenomegaly and other symptoms, which has a significant impact on patients' quality of life. Although traditional treatments, such as the Janus kinase inhibitor ruxolitinib, can alleviate some symptoms, they have limited effect on improving anemia. Therefore, molotinib was introduced as a new treatment option.

According to a retrospective analysis, molotinib not only effectively alleviates the symptoms of MF patients but also improves anemia. Among these patients, 77% had received erythropoietin therapy, while 26 patients received molotinib as first-line treatment, and the remaining 128 patients had a history of multiple previous treatments, especially JAK inhibitors based on ruxolitinib.

One of the important findings of this study is that after treatment with molotinib, most patients experienced significant improvements in symptoms, such as itching, fatigue, sweating, anorexia, and abdominal discomfort. In addition, transfusion dependence also decreased significantly, from an initial 74.7% to 45.6%, which was particularly evident in patients who had previously received JAK therapy. At the same time, for patients who still required transfusions, the median number of red blood cell units required per month decreased from 4 to 2.25, indicating that molotinib played a positive role in reducing the need for transfusions.

In terms of improvement of splenomegaly,62.2% of patients showed spleen shrinkage, with an average shrinkage of 5 cm, while only 24.4% of patients met the 2013 European Leukemia Society criteria for spleen volume shrinkage. This shows that molotinib also has a significant effect in reducing splenomegaly, bringing new hope to the overall treatment of patients.

Although the efficacy of molotinib is remarkable, its safety is also worthy of attention. The most common Grade 3/4 adverse events included thrombocytopenia, infection, and hepatotoxicity. However, the patient's platelet count remained relatively stable throughout treatment. At the last follow-up, a median of 5.48 months, 79% of participants continued on treatment, demonstrating patient tolerance and compliance with the drug.

In summary, molotinib, as an alternative to ruxolitinib, has demonstrated good safety and efficacy in the treatment of patients with myelofibrosis. Real-world data are consistent with clinical trial results, suggesting the importance of molotinib in improving patients' anemia and other related symptoms.MF patients are provided with a wider range of treatment options. With further research and accumulation of clinical data, molotinib may become a new standard for MF treatment in the future, helping more patients improve their quality of life and achieve better treatment effects.

Reference materials:https://www.bloodcancerstoday.com/post/efficacy-of-momelotinib-in-reducing-anemia-in-mf-confirmed-with-real-world-data